Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over

Crovalimab (Piasky, Roche) is indicated for the 'treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria:

• in patients with haemolysis with clinical symptom(s) indicative of high disease activity.

• in patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.'

The dosage schedule is available in the summary of product characteristics for crovalimab.

The list price for crovalimab is £9,500 per 340‑mg vial (excluding VAT; company submission accessed September 2024).

The company has a commercial arrangement. This makes crovalimab available to the NHS with a discount. The size of the discount is commercial in confidence.